Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/48204
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- IOC - Artigos de Periódicos [12642]
Metadata
Mostrar registro completo
AUTHOPHAGY AS A TARGET FOR DRUG DEVELOPMENT OF SKIN INFECTION CAUSED BY MYCOBACTERIA
Autor(es)
Afiliação
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
David Geffen School of Medicine. Division of Dermatology. Los Angeles, CA, United States.
University of Michigan, Ann Arbor. Department of Surgery. Ann Arbor, MI, United States.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Centro de Referência Helio Fraga. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
David Geffen School of Medicine. Division of Dermatology. Los Angeles, CA, United States.
University of Michigan, Ann Arbor. Department of Surgery. Ann Arbor, MI, United States.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Centro de Referência Helio Fraga. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Pathogenic mycobacteria species may subvert the innate immune mechanisms and can
modulate the activation of cells that cause disease in the skin. Cutaneous mycobacterial
infection may present different clinical presentations and it is associated with stigma,
deformity, and disability. The understanding of the immunopathogenic mechanisms
related to mycobacterial infection in human skin is of pivotal importance to identify
targets for new therapeutic strategies. The occurrence of reactional episodes and
relapse in leprosy patients, the emergence of resistant mycobacteria strains, and the
absence of effective drugs to treat mycobacterial cutaneous infection increased the
interest in the development of therapies based on repurposed drugs against
mycobacteria. The mechanism of action of many of these therapies evaluated is linked
to the activation of autophagy. Autophagy is an evolutionary conserved lysosomal
degradation pathway that has been associated with the control of the mycobacterial
bacillary load. Here, we review the role of autophagy in the pathogenesis of cutaneous
mycobacterial infection and discuss the perspectives of autophagy as a target for drug
development and repurposing against cutaneous mycobacterial infection.
Compartilhar